These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28471961)

  • 1. Efficacy and safety of desmoteplase in acute ischemic stroke patients: A systematic review and meta-analysis.
    Li X; Ling L; Li C; Ma Q
    Medicine (Baltimore); 2017 May; 96(18):e6667. PubMed ID: 28471961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.
    Hacke W; Albers G; Al-Rawi Y; Bogousslavsky J; Davalos A; Eliasziw M; Fischer M; Furlan A; Kaste M; Lees KR; Soehngen M; Warach S;
    Stroke; 2005 Jan; 36(1):66-73. PubMed ID: 15569863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Tolerability of Desmoteplase Within 3 to 9 Hours After Symptoms Onset in Japanese Patients With Ischemic Stroke.
    Mori E; Minematsu K; Nakagawara J; Hasegawa Y; Nagahiro S; Okada Y; Truelsen T; Lindsten A; Ogawa A; Yamaguchi T;
    Stroke; 2015 Sep; 46(9):2549-54. PubMed ID: 26251244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset.
    Furlan AJ; Eyding D; Albers GW; Al-Rawi Y; Lees KR; Rowley HA; Sachara C; Soehngen M; Warach S; Hacke W;
    Stroke; 2006 May; 37(5):1227-31. PubMed ID: 16574922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke).
    von Kummer R; Mori E; Truelsen T; Jensen JS; Grønning BA; Fiebach JB; Lovblad KO; Pedraza S; Romero JM; Chabriat H; Chang KC; Dávalos A; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A; Albers GW;
    Stroke; 2016 Dec; 47(12):2880-2887. PubMed ID: 27803391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
    Albers GW; von Kummer R; Truelsen T; Jensen JK; Ravn GM; Grønning BA; Chabriat H; Chang KC; Davalos AE; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A;
    Lancet Neurol; 2015 Jun; 14(6):575-84. PubMed ID: 25937443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desmoteplase for Acute Ischemic Stroke: A Systematic Review and Metaanalysis of Randomized Controlled Trials.
    Elmaraezy A; Abushouk AI; Saad S; Eltoomy M; Mahmoud O; Hassan HM; Aboelmakarem A; Fotoh AA; Althaher F; Huy NT; Hirayama K
    CNS Neurol Disord Drug Targets; 2017; 16(7):789-799. PubMed ID: 27978795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.
    Hacke W; Furlan AJ; Al-Rawi Y; Davalos A; Fiebach JB; Gruber F; Kaste M; Lipka LJ; Pedraza S; Ringleb PA; Rowley HA; Schneider D; Schwamm LH; Leal JS; Söhngen M; Teal PA; Wilhelm-Ogunbiyi K; Wintermark M; Warach S
    Lancet Neurol; 2009 Feb; 8(2):141-50. PubMed ID: 19097942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase.
    Fiebach JB; Al-Rawi Y; Wintermark M; Furlan AJ; Rowley HA; Lindstén A; Smyej J; Eng P; Warach S; Pedraza S
    Stroke; 2012 Jun; 43(6):1561-6. PubMed ID: 22474060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial program.
    von Kummer R; Albers GW; Mori E;
    Int J Stroke; 2012 Oct; 7(7):589-96. PubMed ID: 22989394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refinement of the magnetic resonance diffusion-perfusion mismatch concept for thrombolytic patient selection: insights from the desmoteplase in acute stroke trials.
    Warach S; Al-Rawi Y; Furlan AJ; Fiebach JB; Wintermark M; Lindstén A; Smyej J; Bharucha DB; Pedraza S; Rowley HA
    Stroke; 2012 Sep; 43(9):2313-8. PubMed ID: 22738918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desmoteplase.
    Paciaroni M; Medeiros E; Bogousslavsky J
    Expert Opin Biol Ther; 2009 Jun; 9(6):773-8. PubMed ID: 19456211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombolysis for acute ischaemic stroke.
    Wardlaw JM; Zoppo G; Yamaguchi T; Berge E
    Cochrane Database Syst Rev; 2003; (3):CD000213. PubMed ID: 12917889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.
    Stroke; 1997 Nov; 28(11):2109-18. PubMed ID: 9368550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis.
    Carr SJ; Wang X; Olavarria VV; Lavados PM; Rodriguez JA; Kim JS; Lee TH; Lindley RI; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Woodward M; Chalmers J; Anderson CS; Robinson TG;
    Stroke; 2017 Sep; 48(9):2605-2609. PubMed ID: 28739832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study).
    Robinson TG; Wang X; Arima H; Bath PM; Billot L; Broderick JP; Demchuk AM; Donnan GA; Kim JS; Lavados PM; Lee TH; Lindley RI; Martins SCO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Nguyen TH; Wang JG; Woodward M; Chalmers J; Anderson CS;
    Stroke; 2017 Jul; 48(7):1877-1883. PubMed ID: 28619989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desmoteplase for Acute Ischemic Stroke within 3 to 9 Hours after Symptom Onset: Evidence from Randomized Controlled Trials.
    Shi L; Liang F; Li Y; Shao A; Zhou K; Yu J; Zhang J
    Sci Rep; 2016 Sep; 6():33989. PubMed ID: 27671010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
    Khatri P; Kleindorfer DO; Devlin T; Sawyer RN; Starr M; Mejilla J; Broderick J; Chatterjee A; Jauch EC; Levine SR; Romano JG; Saver JL; Vagal A; Purdon B; Devenport J; Pavlov A; Yeatts SD;
    JAMA; 2018 Jul; 320(2):156-166. PubMed ID: 29998337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.
    del Zoppo GJ; Higashida RT; Furlan AJ; Pessin MS; Rowley HA; Gent M
    Stroke; 1998 Jan; 29(1):4-11. PubMed ID: 9445320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of Thrombolysis and Statins in Acute Stroke Is Safe: Results of the STARS Randomized Trial (Stroke Treatment With Acute Reperfusion and Simvastatin).
    Montaner J; Bustamante A; García-Matas S; Martínez-Zabaleta M; Jiménez C; de la Torre J; Rubio FR; Segura T; Masjuán J; Cánovas D; Freijo M; Delgado-Mederos R; Tejada J; Lago A; Bravo Y; Corbeto N; Giralt D; Vives-Pastor B; de Arce A; Moniche F; Delgado P; Ribó M;
    Stroke; 2016 Nov; 47(11):2870-2873. PubMed ID: 27758944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.